APLS:NSD-Apellis Pharmaceuticals Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 37.63

Change

-0.12 (-0.32)%

Market Cap

USD 3.74B

Volume

0.74M

Avg Analyst Target

USD 66.94 (+77.88%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


Apellis Pharmaceuticals Inc (APLS) Stock Analysis:
Based on the Apellis Pharmaceuticals Inc stock forecasts from 12 analysts, the average analyst target price for Apellis Pharmaceuticals Inc is USD 66.94 over the next 12 months. Apellis Pharmaceuticals Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Apellis Pharmaceuticals Inc is Slightly Bearish, which is based on 3 positive signals and 4 negative signals. At the last closing, Apellis Pharmaceuticals Inc’s stock price was USD 37.63. Apellis Pharmaceuticals Inc’s stock price has changed by -3.17% over the past week, -8.68% over the past month and -21.65% over the last year.

About

Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. Its lead product candidate is pegcetacoplan that is in Phase II ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-01-20 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna Inc

-6.55 (-3.76%)

USD83.01B 12.27 12.33
REGN Regeneron Pharmaceuticals Inc

-3.73 (-0.60%)

USD66.47B 9.89 8.23
VRTX Vertex Pharmaceuticals Incorpo..

-2.23 (-0.97%)

USD58.90B 27.78 15.97
ALXN Alexion Pharmaceuticals Inc

N/A

USD40.34B 59.23 42.56
BNTX BioNTech SE

-5.13 (-3.17%)

USD39.21B 5.08 5.67
BGNE BeiGene Ltd

+14.52 (+6.13%)

USD24.26B N/A N/A
SGEN Seagen Inc

+0.51 (+0.38%)

USD23.82B 55.02 44.86
GMAB Genmab A/S

-0.36 (-1.04%)

USD23.35B 53.31 6.21
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A
RPRX Royalty Pharma plc

-0.66 (-1.65%)

USD17.17B 20.75 11.89

ETFs Containing APLS

Symbol Name Weight Mer Price(Change) Market Cap
LABU Direxion Shares ETF Trust.. 0.00 % 1.02 %

-1.01 (-5.03%)

USD0.95B
SBIO ALPS ETF Trust - ALPS Med.. 0.00 % 0.50 %

-0.87 (-2.46%)

USD0.18B
XBI SPDR S&P Biotech ETF 0.00 % 0.35 %

-1.53 (-1.64%)

USD7.11B

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -20.41% 37% F 17% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -20.41% 37% F 17% F
Trailing 12 Months  
Capital Gain -21.65% 78% C+ 38% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -21.65% 78% C+ 38% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 34.23% 69% D+ 79% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 34.23% 69% D+ 79% C+
Risk Return Profile  
Volatility (Standard Deviation) 50.94% 60% D- 33% F
Risk Adjusted Return 67.20% 93% A 83% B
Market Capitalization 3.74B 93% A 84% B
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 106.11 1% F 1% F
Price / Cash Flow Ratio -23.30 86% B 84% B
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -2,144.31% 2% F 8% F
Return on Invested Capital -58.25% 42% F 15% F
Return on Assets -30.60% 37% F 11% F
Debt to Equity Ratio 175.42% 8% F 11% F
Technical Ratios  
Short Ratio 8.31 15% F 8% F
Short Percent 9.46% 20% F 18% F
Beta 1.56 32% F 23% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

Discussions

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector